Immunohistochemical staining for FOXO3a of breast cancer tumor tissues

Slides:

Advertisements

Similar presentations

Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:

Advertisements

Figure 4. Histologic, immunohistochemical analyses of inflammatory myofibroblastic tumor (IMT) at metastasis diagnosis after complete surgical resection.

AG-221 induces the differentiation of IDH2R140Q blasts along myeloid lineages in primary human AML xenograft models. AG-221 induces the differentiation.

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

Effects of SC144 on in vivo ovarian tumor.

Whole-exome sequencing identifies NF1 mutations in tumors of melanoma patients exhibiting resistance to vemurafenib. Whole-exome sequencing identifies.

The summary page for cancer profiles.

Increase in beige/brown adipocyte characteristics in the xenografts from additional breast cancer cell lines. Increase in beige/brown adipocyte characteristics.

Supplementary Fig S1, Zembutsu H et al.

NICD1 immunohistochemical staining in normal and tumor tissue.

Cell viability assay in NSCLC cell lines in response to gefitinib and Taxol. Cell viability assay in NSCLC cell lines in response to gefitinib and Taxol.

Representative photomicrographs of immunohistochemical staining for Wilms’ tumor 1 (WT1) and cleaved caspase-3 in mouse kidney sections at 10, 20, and.

Immunoperoxidase stainings for HLA-DR (A and B) and HLA-DP (C and D) in jejunal biopsy specimens from a healthy control (A and C) and from a type 1 diabetic.

Significant pathological changes and activation of Nrf2 pathway in the glomeruli of human diabetic nephropathy patients. Significant pathological changes.

Bath application of MEK inhibitor U0126 impairs PTP expression in B2-B2 soma pairs. Bath application of MEK inhibitor U0126 impairs PTP expression in B2-B2.

The sesquiterpene lactone PN up-regulates MDM2 and p53 proteins.

Immunohistochemical detection of 8-OHdG by use of the 1F7 monoclonal antibody in oligomer-treated PC3 prostate cancer cells. a, control untreated peripheral.

Effects of PS-341 on apoptosis in orthotopic human pancreatic tumors.

Immunohistochemical analyses of SHH expression levels in nonmalignant prostate and adenocarcinoma tissues. Immunohistochemical analyses of SHH expression.

Expression analysis of IGFBP-3 using human whole-genome microarray.

Correlation of RSPO expression to LGR5 expansion in gastric cancer.

Stimulatory effect induced by docetaxel, gefitinib, and cyclopamine on MMP (A) and (B) cytosolic cytochrome c level. Stimulatory effect induced by docetaxel,

NicA2-J1 prevents nicotine addiction–like behavior during withdrawal

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

FAK overexpression in invasive human breast cancer and DCIS

Tlr4−/− attenuates symptomatic parameters of gut toxicity: diarrhea and weight loss. Tlr4−/− attenuates symptomatic parameters of gut toxicity: diarrhea.

Cytokine expression in the ileum and colon.

TSA-mediated changes in cell cycle inhibitor proteins.

MAPJD expression in lung cancers.

In vivo thrombosis of tumor vasculature.

Antitumor activity of MLN8237 against TNBC patient-derived tumor xenografts (PDTX) in vivo. Antitumor activity of MLN8237 against TNBC patient-derived.

Anti-Flk-1 mAb treatment reduces vessel density in tumors.

Cisplatin plus PTUPB decreases proliferation and angiogenesis but increases apoptosis as determined by immunohistochemical (IHC) analysis. Cisplatin plus.

TDP1 and TOP1 protein levels vary widely in colorectal cancer (CRC) patient samples. TDP1 and TOP1 protein levels vary widely in colorectal cancer (CRC)

Immunohistochemical detection of nuclear and cytoplasmic YB-1 in osteosarcoma and synovial sarcoma. Immunohistochemical detection of nuclear and cytoplasmic.

ALDH1A3 expression levels are inversely correlated with the survival of patients with resectable mass-forming and advanced cholangiocarcinoma, respectively.

Endothelial cells/microvasucles are increased in prostate cancer versus normal tissues. Endothelial cells/microvasucles are increased in prostate cancer.

Angiogenesis in tumors formed by cells varying in the expression of CXCR2. Angiogenesis in tumors formed by cells varying in the expression of CXCR2. A,

Curcumin enhances effects of bortezomib to inhibit angiogenesis in multiple myeloma tumor samples. Curcumin enhances effects of bortezomib to inhibit angiogenesis.

Immunohistochemical analysis of dUTPase in human breast adenocarcinoma

Immunohistochemical staining of primary and metastatic prostatic carcinomas with anticyclin D1 and anti-Ki67 monoclonal antibodies. Immunohistochemical.

Xenograft regrowth studies.

GR CAFs modulate the EGFR-TKI response in cocultured tumor cells.

Mir-128 reduction in breast cancer tissues correlates chemotherapy resistance and poor patient survival. Mir-128 reduction in breast cancer tissues correlates.

Micro-PET/CT images of 64Cu-Sar-chTNT-3 in MAD109-bearing BALB/c mice following VP-16 pretreatment. Micro-PET/CT images of 64Cu-Sar-chTNT-3 in MAD109-bearing.

Ketogenic diets combined with fractionated radiation treatment results in decreased immunoreactive PCNA in tumor tissue. Ketogenic diets combined with.

Neutralization of CSF1 and Ad5-HRG treatment.

Three-day biodistribution of 125I-labeled chTNT-3 administered at (A) 1, 2, or 3 days after pretreatment with VP-16 (30 mg/kg) in MAD109 bearing BALB/c.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

Induction of liver NQO1 activity in juvenile female rats treated for 3 d (10 mg/kg qd SERMs or 0.1 mg/kg qd E2 or vehicle control). Induction of liver.

CRA inhibits the growth of human tumor xenografts in vivo.

Changes in signal transduction pathway induced by gefitinib.

Increased levels of acetylated histone H3 are observed in normal PBMCs and circulating tumor cells obtained from patients post-depsipeptide treatment.

PSMA expression in pre- and posttreatment prostate carcinoma serum.

Expression of versican promoted breast cancer cell tumor formation and self-renewal in vivo. Expression of versican promoted breast cancer cell tumor formation.

Effect of CDV on human SF7796 xenografts in vivo.

Progastrin staining in colon adenomas and adenocarcinomas.

Histology (H&E; original magnification, ×100 for B-2P/C-12P/C-64P and ×40 for C-10P; top) of small-sized lung adenocarcinomas and immunohistochemical staining.

Specific reaction with MIB1, M30, and CD31 monoclonal antibodies in primary human cervical carcinoma before (A, C, and E) and after (B, D, and F) Tam treatment.

A, TSG-6 staining in human prostate.

Inhibition of spontaneous pulmonary metastasis and prolonged survival after removal of primary tumor and intratracheal delivery of rAAV2/5-VAS. Inhibition.

Cabozantinib causes significant tumor cell elimination in vivo, but modest apoptosis induction in vitro. Cabozantinib causes significant tumor cell elimination.

Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.

Elevated STAT3 phosphorylation and RANTES levels in tamoxifen-treated breast cancer cells. Elevated STAT3 phosphorylation and RANTES levels in tamoxifen-treated.

Immunohistochemical determination of TIM-3 expression in ccRCC.

I3C reduces the level of Cdc25A protein in breast cancer cells.

PEGPH20 depletes HA and decompresses intratumoral vessels.

MITF-low/NF-κB–high transcriptional class is present and associated with resistance to MAPK pathway inhibition in human tumors. MITF-low/NF-κB–high transcriptional.

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Presentation transcript:

Immunohistochemical staining for FOXO3a of breast cancer tumor tissues. Immunohistochemical staining for FOXO3a of breast cancer tumor tissues. A, tumor tissue sample obtained from breast cancer patients before and 4 wk after treatment with gefitinib were stained with FOXO3a antibody. Control group of patients received no treatment between primary biopsy and subsequent surgical tumor resection. In the control group, cytoplasmic staining can be observed in both pre- and post-cases, whereas in the gefitinib-treated group, cytoplasmic staining in pretreatment cases changes to predominantly nuclear staining after treatment (post; magnification, ×200). B, statistical analysis using a mixed-design ANOVA with post hoc Bonferroni test revealed significant increase in FOXO3a nuclear staining intensity with a concomitant decrease in cytoplasmic staining after gefitinib treatment, whereas no such changes were observed in the control group. Janna Krol et al. Mol Cancer Ther 2007;6:3169-3179 ©2007 by American Association for Cancer Research